247 related articles for article (PubMed ID: 36574622)
1. Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies.
Quach DH; Lulla P; Rooney CM
Blood; 2023 Feb; 141(8):877-885. PubMed ID: 36574622
[TBL] [Abstract][Full Text] [Related]
2. Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults.
Galletta TJ; Lane A; Lutzko C; Leemhuis T; Cancelas JA; Khoury R; Wang YM; Hanley PJ; Keller MD; Bollard CM; Davies SM; Grimley MS; Rubinstein JD
Transplant Cell Ther; 2023 May; 29(5):305-310. PubMed ID: 36736781
[TBL] [Abstract][Full Text] [Related]
3. A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells.
Quach DH; Becerra-Dominguez L; Rouce RH; Rooney CM
J Transl Med; 2019 Jul; 17(1):240. PubMed ID: 31340822
[TBL] [Abstract][Full Text] [Related]
4. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.
Tzannou I; Papadopoulou A; Naik S; Leung K; Martinez CA; Ramos CA; Carrum G; Sasa G; Lulla P; Watanabe A; Kuvalekar M; Gee AP; Wu MF; Liu H; Grilley BJ; Krance RA; Gottschalk S; Brenner MK; Rooney CM; Heslop HE; Leen AM; Omer B
J Clin Oncol; 2017 Nov; 35(31):3547-3557. PubMed ID: 28783452
[TBL] [Abstract][Full Text] [Related]
5. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.
Cruz CR; Micklethwaite KP; Savoldo B; Ramos CA; Lam S; Ku S; Diouf O; Liu E; Barrett AJ; Ito S; Shpall EJ; Krance RA; Kamble RT; Carrum G; Hosing CM; Gee AP; Mei Z; Grilley BJ; Heslop HE; Rooney CM; Brenner MK; Bollard CM; Dotti G
Blood; 2013 Oct; 122(17):2965-73. PubMed ID: 24030379
[TBL] [Abstract][Full Text] [Related]
6. Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant.
Rubinstein JD; Lutzko C; Leemhuis T; Zhu X; Pham G; Ray L; Thomas S; Dourson C; Wilhelm J; Lane A; Cancelas JA; Lipps D; Ferrell J; Hanley PJ; Keller MD; Bollard CM; Wang YM; Davies SM; Nelson AS; Grimley MS
Blood Adv; 2022 May; 6(9):2897-2907. PubMed ID: 35108727
[TBL] [Abstract][Full Text] [Related]
7. Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation Recipients.
Rubinstein JD; Jodele S; Heyenbruch D; Wilhelm J; Thomas S; Lutzko C; Zhu X; Leemhuis T; Cancelas JA; Keller M; Bollard CM; Hanley PJ; Boghdadly ZE; Mims A; Davies SM; Grimley MS; Nelson AS
Transplant Cell Ther; 2022 Feb; 28(2):116.e1-116.e7. PubMed ID: 34785398
[TBL] [Abstract][Full Text] [Related]
8. Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application.
Sun J; Huye LE; Lapteva N; Mamonkin M; Hiregange M; Ballard B; Dakhova O; Raghavan D; Durett AG; Perna SK; Omer B; Rollins LA; Leen AM; Vera JF; Dotti G; Gee AP; Brenner MK; Myers DG; Rooney CM
J Immunother Cancer; 2015; 3():5. PubMed ID: 25734008
[TBL] [Abstract][Full Text] [Related]
9. Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease.
Kinoshita H; Mandava M; Jensen-Wachspress M; Lang H; Joy E; Tanna J; McCann CD; O'Brien S; Burnett S; Shibli A; Hoq F; Bhatia M; Hanley PJ; Dávila Saldaña B; Mahadeo KM; Bollard CM; Keller MD; Abraham A
Blood Adv; 2023 May; 7(10):2105-2116. PubMed ID: 36516084
[TBL] [Abstract][Full Text] [Related]
10. Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation.
Shafat MS; Mehra V; Peggs KS; Roddie C
Front Immunol; 2020; 11():1694. PubMed ID: 32849591
[TBL] [Abstract][Full Text] [Related]
11. Transgenic CD8αβ co-receptor rescues endogenous TCR function in TCR-transgenic virus-specific T cells.
Bajwa G; Lanz I; Cardenas M; Brenner MK; Arber C
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33148692
[TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes.
Naik S; Nicholas SK; Martinez CA; Leen AM; Hanley PJ; Gottschalk SM; Rooney CM; Hanson IC; Krance RA; Shpall EJ; Cruz CR; Amrolia P; Lucchini G; Bunin N; Heimall J; Klein OR; Gennery AR; Slatter MA; Vickers MA; Orange JS; Heslop HE; Bollard CM; Keller MD
J Allergy Clin Immunol; 2016 May; 137(5):1498-1505.e1. PubMed ID: 26920464
[TBL] [Abstract][Full Text] [Related]
13. Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT.
Qian C; Wang Y; Reppel L; D'aveni M; Campidelli A; Decot V; Bensoussan D
Bone Marrow Transplant; 2018 Feb; 53(2):114-122. PubMed ID: 29058697
[TBL] [Abstract][Full Text] [Related]
14. The effects of β
Kunz HE; Agha NH; Hussain M; LaVoy EC; Smith KA; Mylabathula P; Diak D; Baker FL; O'Connor DP; Bond RA; Katsanis E; Bollard CM; Simpson RJ
Cell Stress Chaperones; 2020 Nov; 25(6):993-1012. PubMed ID: 32779001
[TBL] [Abstract][Full Text] [Related]
15. Identification of the best-suited donor for generating virus-specific T cells.
Tasnády S; Karászi É; Szederjesi A; Bihari G; Juhász Z; Hardi A; Kriván G; Kállay K; Reményi P; Sinkó J; Mikala G; Réti M; Masszi T
Vox Sang; 2020 Jan; 115(1):18-26. PubMed ID: 31667887
[TBL] [Abstract][Full Text] [Related]
16. Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells.
Perez C; Gruber I; Arber C
Front Immunol; 2020; 11():583716. PubMed ID: 33262761
[TBL] [Abstract][Full Text] [Related]
17. First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia.
Peinemann F; Bartel C; Grouven U
Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD006407. PubMed ID: 23881658
[TBL] [Abstract][Full Text] [Related]
18. High-intensity interval training in allogeneic adoptive T-cell immunotherapy - a big HIT?
Heinemann NC; Tischer-Zimmermann S; Wittke TC; Eigendorf J; Kerling A; Framke T; Melk A; Heuft HG; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
J Transl Med; 2020 Apr; 18(1):148. PubMed ID: 32238166
[TBL] [Abstract][Full Text] [Related]
19. Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients.
Nelson AS; Heyenbruch D; Rubinstein JD; Sabulski A; Jodele S; Thomas S; Lutzko C; Zhu X; Leemhuis T; Cancelas JA; Keller M; Bollard CM; Hanley PJ; Davies SM; Grimley MS
Blood Adv; 2020 Nov; 4(22):5745-5754. PubMed ID: 33216887
[TBL] [Abstract][Full Text] [Related]
20. Establishment and Operation of a Third-Party Virus-Specific T Cell Bank within an Allogeneic Stem Cell Transplant Program.
Withers B; Clancy L; Burgess J; Simms R; Brown R; Micklethwaite K; Blyth E; Gottlieb D
Biol Blood Marrow Transplant; 2018 Dec; 24(12):2433-2442. PubMed ID: 30172015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
